Tag: helix biopharma
May 1, 2019
Helix BioPharma Gives Update on L-DOS47 Phase II Study
Helix BioPharma announced the Trial Steering Committee reviewed safety data from the first dosing cohort of the Company’s LDOS003 study. June 8, 2018
Helix BioPharma Closes Private Placement
Helix BioPharma (TSX:HBP) an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it... February 23, 2018
Helix BioPharma Appoints Deloitte as Strategic Advisor to Explore Partnering and Licensing Opportunities
Helix BioPharma (TSX:HBP) a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today... December 14, 2017
Helix BioPharma Shares Fiscal 2018 Q1 Financial Results
Helix BioPharma announced its financial results for the first quarter of their 2018 fiscal year. September 28, 2017
Helix BioPharma Gets FDA Approval to Accelerate Dose Escalation in Trial
Helix BioPharma announced that the FDA approved an amendment to their phase I study, protocol LDOS001, to accelerate the dose... September 1, 2017
Helix BioPharma Closes Private Placement
Helix BioPharma announced it closed a private placement financing option, which resulted in gross proceeds of $1,311,000. August 22, 2017
